Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Treasury Shares (2016 - 2025)

Ironwood Pharmaceuticals' Treasury Shares history spans 15 years, with the latest figure at $315000.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 71.58% year-over-year to $315000.0; the TTM value through Dec 2025 reached $315000.0, down 71.58%, while the annual FY2025 figure was $315000.0, 71.58% down from the prior year.
  • Treasury Shares for Q4 2025 was $315000.0 at Ironwood Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.3 million in Q4 2023 and bottomed at $315000.0 in Q4 2025.
  • The 5-year median for Treasury Shares is $3.9 million (2021), against an average of $3.0 million.
  • The largest annual shift saw Treasury Shares soared 559.23% in 2021 before it tumbled 79.25% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $3.9 million in 2021, then rose by 11.03% to $4.3 million in 2022, then grew by 24.53% to $5.3 million in 2023, then crashed by 79.25% to $1.1 million in 2024, then plummeted by 71.58% to $315000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Treasury Shares are $315000.0 (Q4 2025), $1.1 million (Q4 2024), and $5.3 million (Q4 2023).